T2 Biomarkers Predictive Value in Occupational Asthma After Cessation of Exposure.
Key facts
- Who runs it
- University Hospital, Strasbourg, France
- Where
- France1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Withdrawn
- Started
- Jun 2025
- Ended
- Jun 2026
- Type of study
- Interventional
- Treatments tested
- Measure of T2 biomarkers
- Record updated
- 23 June 2026
- Why it stopped
- Because of the negative results reported in other studies
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- Age over 18
- Diagnosis of occupational asthma by specific inhalation challenge
- Exposure to sensitizing agent avoided or reduced
- Able to understand the aims and risks of the research and to give free and informed consent
- For women of childbearing age: effective contraception in progress
- Benefiting from social security coverage
Who cannot take part
- Impossibility of giving the subject informed information (subject in emergency situation, difficulties in understanding the subject)
- Subject under court protection
- Subject under guardianship or curatorship
- Pregnant or breast-feeding patient
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Occupational exposure is known to cause 15% of asthma cases. The main treatment for occupational asthma is to stop exposure if possible. Although, remission of occupational asthma only occurs in only 30 % of patients after cessation of exposure. There is currently no way of predicting which patients will go into remission after cessation of exposure.
Read full original descriptionShow less
In non-occupational asthma, the inflammatory biomarker T2 has allowed the entry into personalized medicine and can predict future exacerbations.
The investigators hypothesize that T2 biomarkers could be predictive markers for remission in occupational asthma after exposure cessation.
The investigators intend to carry out a follow-up study at the University Hospital of Strasbourg to perform the non-specific bronchial hyperresponsiveness test to assess remission in patients diagnosed with occupational asthma and to compare baseline T2 biomarkers in remission and non remission patients.
The group in the trial
- patients with occupational asthmaOther group
Treatment: Measure of T2 biomarkers
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 23 June 2026